Polatuzumab vedotin targets CD79b on B cells, is internalized, and releases MMAE that binds the vinca site on beta-tubulin to inhibit microtubule polymerization, causing G2/M arrest and apoptosis; beta-tubulin expression alone does not make cells susceptible.